Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Effect of Insurance Type on Stage at Presentation, Surgical Approach, Tumor Recurrence and Cancer-Specific Survival in Resectable Non-Small Lung Cancer Patients.
Risk Manag Healthc Policy. 2020 Jun 12;13:559-569. doi: 10.2147/RMHP.S244344. eCollection 2020.
Risk Manag Healthc Policy. 2020.
PMID: 32607024
Free PMC article.
Outcomes of pulmonary resection in non-small cell lung cancer patients older than 70 years old.
Tantraworasin A, Siwachat S, Tanatip N, Lertprasertsuke N, Kongkarnka S, Euathrongchit J, Wannasopha Y, Suksombooncharoen T, Chewaskulyong B, Taioli E, Saeteng S.
Tantraworasin A, et al. Among authors: suksombooncharoen t.
Asian J Surg. 2020 Jan;43(1):154-165. doi: 10.1016/j.asjsur.2019.03.006. Epub 2019 Mar 18.
Asian J Surg. 2020.
PMID: 30898491
Free article.
Item in Clipboard
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, Chen MH, Suksombooncharoen T, Ikeda M, Lee MA, Chen JS, Potemski P, Burris HA 3rd, Ostwal V, Tanasanvimon S, Morizane C, Zaucha RE, McNamara MG, Avallone A, Cundom JE, Breder V, Tan B, Shimizu S, Tougeron D, Evesque L, Petrova M, Zhen DB, Gillmore R, Gupta VG, Dayyani F, Park JO, Buchschacher GL Jr, Rey F, Kim H, Wang J, Morgan C, Rokutanda N, Żotkiewicz M, Vogel A, Valle JW.
Oh DY, et al. Among authors: suksombooncharoen t.
Lancet Gastroenterol Hepatol. 2024 May 29:S2468-1253(24)00095-5. doi: 10.1016/S2468-1253(24)00095-5. Online ahead of print.
Lancet Gastroenterol Hepatol. 2024.
PMID: 38823398
Item in Clipboard
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators.
Powles T, et al.
N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117.
N Engl J Med. 2024.
PMID: 38446675
Clinical Trial.
Item in Clipboard
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Lee MA, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, Żotkiewicz M, Kurland JF, Cohen G, Valle JW.
Oh DY, et al. Among authors: suksombooncharoen t.
Future Oncol. 2023 Nov;19(34):2277-2289. doi: 10.2217/fon-2023-0468. Epub 2023 Sep 25.
Future Oncol. 2023.
PMID: 37746835
Review.
Item in Clipboard
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators.
Kelley RK, et al.
Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.
Lancet. 2023.
PMID: 37075781
Clinical Trial.
Item in Clipboard
Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study.
Luangnara A, Kiratikanon S, Ketpueak T, Suksombooncharoen T, Charoentum C, Chewaskulyong B, Tovanabutra N, Chiewchanvit S, Nochaiwong S, Chuamanochan M.
Luangnara A, et al. Among authors: suksombooncharoen t.
Front Immunol. 2022 Oct 20;13:965550. doi: 10.3389/fimmu.2022.965550. eCollection 2022.
Front Immunol. 2022.
PMID: 36341419
Free PMC article.
Item in Clipboard
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Ah Lee M, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, He P, Kurland JF, Cohen G, Valle JW.
Oh DY, et al. Among authors: suksombooncharoen t.
NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.
NEJM Evid. 2022.
PMID: 38319896
Item in Clipboard
Cite
Cite